Eiskjaer H, Nielsen C B, Pedersen E B
Department of Medicine and Nephrology C, Skejby Hospital, Arhus, Denmark.
J Hypertens. 1996 Jan;14(1):99-106.
To study the influence of blood pressure reduction with sodium nitroprusside on the renal glomerular and tubular actions of atrial natriuretic peptide.
Forty-nine healthy subjects were examined in four different groups receiving placebo, sodium nitroprusside alone, atrial natriuretic peptide alone (10 ng/kg per min), or sodium nitroprusside and atrial natriuretic peptide in combination. The infusion rate of sodium nitroprusside was gradually increased until a 10 mmHg decrease in diastolic blood pressure was obtained.
Lithium clearance was used to evaluate segmental tubular reabsorption.
In the placebo group neither renal nor hormonal parameters were changed. Except for a fall in urinary flow, sodium nitroprusside alone had no effect on renal parameters. Urinary excretion of cyclic GMP (cGMP) was slightly increased, whereas the plasma cGMP level was not changed in response to sodium nitroprusside. The plasma aldosterone level was elevated during sodium nitroprusside infusion, although neither the plasma angiotensin II level nor the plasma atrial natriuretic peptide level were changed. Atrial natriuretic peptide alone caused an increase in filtration fraction and a decrease in renal plasma flow. Urinary sodium excretion, fractional sodium excretion, and urinary flow were increased, and distal fractional tubular sodium absorption decreased, whereas lithium clearance and proximal fractional tubular re-absorption were not changed by atrial natriuretic peptide. Atrial natriuretic peptide alone caused a decrease in plasma aldosterone and an increase in plasma and urinary cGMP levels. During blood pressure reduction with sodium nitroprusside, atrial natriuretic peptide caused no changes in the renal parameters except for an increase in filtration fraction. Thus, the increase in urinary sodium excretion (-8 versus +37 micromol/min) and the decrease in distal fractional sodium excretion (0.0 versus -2.4%) caused by atrial natriuretic peptide were attenuated. The atrial natriuretic peptide-induced changes in proximal fractional tubular reabsorption (-0.5 versus +0.6%) and cGMP were not changed by blood pressure reduction.
Blood pressure reduction causes an attenuation of the natriuretic action of atrial natriuretic peptide in normotensive humans that is at least partly caused by attenuation of the distal tubular action of atrial natriuretic peptide. The results support the hypothesis that the action of atrial natriuretic peptide on distal tubular sodium reabsorption is pressure-dependent in humans.
研究硝普钠降压对心房利钠肽肾小球及肾小管作用的影响。
49名健康受试者被分为四组,分别接受安慰剂、单独使用硝普钠、单独使用心房利钠肽(每分钟10 ng/kg)或硝普钠与心房利钠肽联合使用。硝普钠的输注速率逐渐增加,直至舒张压下降10 mmHg。
采用锂清除率评估肾小管节段性重吸收。
安慰剂组肾脏及激素参数均未改变。单独使用硝普钠除尿量减少外,对肾脏参数无影响。环磷酸鸟苷(cGMP)尿排泄略有增加,而硝普钠输注后血浆cGMP水平未改变。硝普钠输注期间血浆醛固酮水平升高,而血浆血管紧张素II水平和血浆心房利钠肽水平均未改变。单独使用心房利钠肽导致滤过分数增加和肾血浆流量减少。尿钠排泄、钠排泄分数和尿量增加,远端肾小管钠重吸收分数降低,而锂清除率和近端肾小管重吸收分数未因心房利钠肽而改变。单独使用心房利钠肽导致血浆醛固酮降低,血浆和尿cGMP水平升高。在硝普钠降压过程中,心房利钠肽除使滤过分数增加外,对肾脏参数无影响。因此,心房利钠肽引起的尿钠排泄增加(-8对+37 μmol/min)和远端钠排泄分数降低(0.0对-2.4%)减弱。血压降低未改变心房利钠肽引起的近端肾小管重吸收分数(-0.5对+0.6%)和cGMP的变化。
血压降低导致正常血压人群中心房利钠肽的利钠作用减弱,这至少部分是由于心房利钠肽远端肾小管作用减弱所致。结果支持心房利钠肽对远端肾小管钠重吸收的作用在人类中依赖于血压的假说。